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Abstract: The glycan structures of the receptor binding
domain of the SARS-CoV2 spike glycoprotein expressed in
human HEK293F cells have been studied by using NMR. The
different possible interacting epitopes have been deeply
analysed and characterized, providing evidence of the presence
of glycan structures not found in previous MS-based analyses.
The interaction of the RBD 13C-labelled glycans with different
human lectins, which are expressed in different organs and
tissues that may be affected during the infection process, has
also been evaluated by NMR. In particular, 15N-labelled
galectins (galectins-3, -7 and -8 N-terminal), Siglecs (Siglec-8,
Siglec-10), and C-type lectins (DC-SIGN, MGL) have been
employed. Complementary experiments from the glycoprotein
perspective or from the lectins point of view have permitted to
disentangle the specific interacting epitopes in each case. Based
on these findings, 3D models of the interacting complexes have
been proposed.
Introduction
The current COVID-19 pandemic caused by SARS-CoV-
2 coronavirus represents an enormous health and social
problem.[1, 2] The virus employs a glycosylated spike protein
(S) to bind the angiotensin-converting enzyme 2 (ACE2) of
the host.[3, 4] In many viral infections (influenza, Ebola, SARS-
CoV, among others), glycan-mediated interactions are essen-
tial for the initial contact between the virus and the host.[5–7] In
fact, glycans modulate molecular recognition events not only
in host-pathogen recognition or infections, but also in tissue
differentiation, cell signalling, immune response, and cancer,
besides contributing to proper protein folding.[8] In SARS-
CoV-2, a receptor binding domain (RBD) has been identified
that efficiently binds ACE2. Both ACE2 and the RBD are
glycosylated, although the RBD glycans do not seem to be
directly involved in the interaction, according to the structural
data available so far.[3,4, 9] Additionally, our immune system
contains a variety of glycan-binding proteins (lectins) that are
able to specifically detect and bind diverse glycan-epitopes,
triggering innate responses in a glycan-dependent man-
ner.[10,11] In the SARS-Cov-2 context, a recent study[12] has
suggested the existence of lectin-mediated molecular path-
ways that may contribute to viral infection and immune
exacerbation, identifying some lectins that bind to the RBD.
From the molecular recognition perspective, unravelling
these viral glycan-host lectin interactions at high resolution
represents a tremendous scientific challenge. Since N-glyco-
sylation is not template-driven, the hallmark is chemical
heterogeneity. Glycoprofile analysis remains technically dif-
ficult given the huge range of possible monosaccharide
combinations and the different ways they can link to each
other. Advances in mass spectrometry (MS) allows achieving
a global perspective of the glycoprofile of the target protein.
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In fact, the glycosylation profile of the spike glycoprotein S
has been recently described.[13–16] However, given the need of
digestion protocols for MS-based methods, molecular recog-
nition studies should be carried out with procedures that only
minimally alter the test samples. In this context, we have
herein applied an NMR protocol[17] to characterize the precise
glycan structures of the two N-linked uniformly 13C-labeled
glycans (at N331 and N343) in the domain B of subunit S1 (SB)
from the RBD (hereinafter referred to as RBD) of SARS-
CoV-2,[4, 18] produced in human HEK293F cells.[19] Addition-
ally, we have dissected the glycan-mediated interactions of
RBD with a variety of human lectins, which are expressed in
different organs and tissues that may be affected during the
infection (Figure 1). For this task, two complementary proto-
cols have been employed. On the one hand, signal changes in
the 2D 1H,13C-HSQC NMR spectra of the 13C-labeled glycans
on the RBD have been monitored upon addition of the
lectins. Alternatively, signal perturbations in the 1H,15N-
TROSY/HSQC spectra of the 15N-labelled lectins in the
presence of the RBD have been assessed to provide
a complementary view on their specific interactions. Our
study provides key structural details on the N-glycan content
on the RBD of SARS-CoV-2 spike protein, especially respect
to the exposed glyco-epitopes at the terminal chains, prone to
participate in lectin recognition. We have identified the
specific glycans in the RBD that are recognized by the
corresponding lectin.
Results and Discussion
Disentangling the Glycoprofile of the RBD Produced in HEK293F
Cells
A NMR-based approach[17,27–31] was employed to perform
the glycoprofile analysis of the N-linked glycans at N331 and
N343 at the SB domain of RBD (residues 328-533). Key
regions of the spectra are shown in Figure 2 and Figure S1. In
particular, the combined analysis of 3D H’,CH NOESY-
HSQC, H’,CH TOCSY-HSQC, and H’[C’],CH and [H’]C’,CH
edited HSQC-[13C,13C]TOCSY-HSQC (Figure 2) allowed to
determine the precise structure of the glycans and their
glycosidic linkages (Table S1). The [H’]C’,CH edited HSQC-
TOCSY-HSQC was instrumental to assign all carbon reso-
nances for every spin system (Figure 2), identifying glycosy-
lated or otherwise chemically modified positions. The pres-
Figure 1. A) Panel of human lectins employed herein along with their
locations in human organs and tissues. B) Major glycan specificities
and binding affinities for DC-SIGN,[20] galectin-7,[21] Siglec-8,[22] galectin-
3,[23] MGL,[24] galectin-8[21] and siglec-10[25] are given. Glycans are
represented in SNFG symbols.[26]
Figure 2. NMR identification of glycan structures on SARS-CoV-2 RBD
glycoprotein. A) Left: detail of the 1H,13C-HSQC of RBD showing the
assignment for most anomeric correlations, represented as SNFG
symbols.[26] Anomeric correlations for Gal, GalNAc and GlcNAc are
identified with a number in brackets. Right: 3D [H’]C’,CH edited
HSQC-TOCSY-HSQC of RBD, selected planes for C1 GalNAc on the
4SulLDN fragment and for C1 GalNAc on 6’SLDN, showing the
correlations to all 13C atoms within the pyranose spin system. Nearby
cross peaks belonging to other spin systems have been veiled for
clarity. B) GalNAc, Gal and GlcNAc containing epitopes in N-linked
glycans on RBD, represented as SNFG symbols.
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ence of terminal N-acetyllactosamine (LacNAc) units was
assessed by the analysis, and appeared also decorated with
a2,3- (3’SLacNAc or 3’SLN) and a2,6-linked sialyl (6’SLac-
NAc or 6’SLN) moieties. The presence of GalNAc-containing
epitopes, b1-4 linked to GlcNAc, was also evident: terminal
GalNAcb1-4GlcNAc (LacdiNAc or LDN) was found, along
with their a2,6-sialylated and 4-O-sulfated derivatives
(6’SLDN and 4SulLDN) that had not been identified in
previous MS analyses of the S protein.[13, 14,16] 4SulLDN was
identified due to the exclusive 1H/13C chemical shifts (Ta-
ble S1) of position 4 of GalNAc.[32] Another relevant obser-
vation was the presence of a high degree of fucosylation, both
at the core and at terminal positions, corresponding to
LewisX (LeX) and fucosylated LDN (LDNF). The presence
of this last epitope was somehow unexpected as it has usually
been related to parasites, and is thought to cause immuno-
genic response in humans.[33–35] With respect to the N-glycan
architecture, although a quantitative analysis is out of the
scope of this study, biantennary complex N-glycans are the
prevalent scaffolds. Signals corresponding to high-mannose-
type N-glycans display almost undetectable intensity, while
the presence of core bisecting GlcNAc was discarded due to
the absence of its characteristic signals (downfield shift of the
H4-C4 correlation for bMan).[36] On the other hand, a minor
degree of additional branching to give tri- and tetra-antennae
was also verified. The branching at the a3-antenna occurs
through further b1-4-linked GlcNAc glycosylation of aMan3,
whose anomeric carbon becomes upfield shifted (Figure 2).[36]
The branching at the a6 antenna is produced by a GlcNAc b1-
6 linkage to aMan6, whose anomeric correlation can be now
distinguished.[36] Additionally, the low intensity of the signals
corresponding to the anomeric positions of bGal moieties in
type I poly-LacNAc structures, strongly suggested the ab-
sence of these elongations.
Protein N-glycosylation is a highly complex and tightly
regulated event, hitherto not fully understood.[37, 38] The use of
glycoproteins as therapeutics has fostered the development of
novel methods to control glycosylation, with special focus on
producer-cell lines, which strongly influence the N-glycosyla-
tion outcome.[39] Different MS-based studies on the glycosy-
lation pattern of the spike protein in HEK293/F cells have
been recently presented.[13–16] However, despite employing
the same expression system, these studies yielded slightly
different results, which could be partially explained by the use
of diverse S proteins (either the trimeric form or the separate
S1 and S2 subunits). Indeed, the specific protein structure has
been proposed as one of the multiple factors influencing
protein glycosylation.[40,41] Our results for the RBD of the S
protein, which contains two glycosylation sites at N331 and
N343, show very important levels of fucosylation (Fuc) and N-
acetyl galactosylation (GalNAc), also reported in some of the
MS-based studies.[13–16] However, our NMR methodology
allows defining the precise chemical nature and structural
details (glycosidic linkages, sulfation) of the epitopes in which
these residues (Fuc, GalNAc) are found. Indeed, glycan
motifs not described earlier, as 4SulLDN, 6’SLDN, LeX, and
LDNF were evident by NMR.
These moieties, along with terminal LacNAc, LDN, 3’SLN
and 6’SLN fragments are predominant epitopes on the outer
chains of the RBD N-glycans. These unexpected findings
prompted us to produce a different 13C-labelled glycoprotein,
the a subunit of the human high-affinity Fc receptor for IgE
(FceRIa),[17,42] using exactly the same conditions used for the
RBD. Interestingly, the superimposition of the 1H,13C-HSQC
spectra of the glycans of RBD and FceRIa evidenced the lack
of all GalNAc-containing cross peaks as well as fucosylated
LDNF and LeX signals in FceRIa, as previously observed by
employing other conditions (Figure S2). Among other factors,
these results suggest that the precise protein structure could
influence the glycosylation pattern.[40, 41, 43–45] Nevertheless, the
NMR methodology described herein allows detecting key
features of the epitopes, as sulfation, rather difficult to detect
by the potent MS approach.[46–48]
Molecular Recognition Studies: The Interaction with Lectins
It has been recently proposed that the spike glycoprotein
is specifically recognized by C-type lectins (Dendritic Cell-
Specific Intercellular adhesion molecule-3-Grabbing Non-
integrin (DC-SIGN) and Macrophage Galactose-type lectin
(MGL)) and by Siglecs expressed in the lung microbiota.[12]
Thus, we focused on deducing the specific epitopes respon-
sible for these interactions. Moreover, we also studied the
interaction with several human galectins (galectins-3, 7 and
8), which are involved in inflammation.[49, 50] It has been
proposed that galectin inhibitors may modulate the cytokine
storm associated to COVID-19 as well as interfering with viral
attack.[51] Thus, NMR experiments both from the glycan and
from the lectin perspectives were carried out to monitor the
lectin/RBD interactions. From the glycan point of view, the
cross peak intensities of the 13C-labelled glycans described
above were compared to those recorded in the presence of the
lectins (Figures 3, 4, 6, and 7). Alternatively, 1H,15N-TROSY/
HSQC experiments allowed analysing the line width pertur-
bations of the amide NMR signals of the 15N-labelled lectins
upon RBD addition (Figure 5 and Figures S4–7). Although
signal broadening depends on many factors and cannot be
directly related with binding affinity, it allowed us to discern
the glycan specificities among the lectins studied.
The Interaction with Galectins
Upon addition of galectin-3, the 1H,13C-HSQC spectrum
of the RBD glycans showed significant, but selective,
reductions in the intensity of diverse cross peaks (Figures 3
and 4). Intensity attenuation was more pronounced for peaks
from LDN, LacNAc and 3’SLacNAc. The observed dramatic
signal broadening evidence the presence of dynamic process-
es in the intermediate exchange regime in the NMR chemical
shift time scale and thus, the presence of a significant
interaction.
Additional information was obtained by observing the
changes in the lectin 1H,15N cross peaks (Figure 5). The results
strongly suggest that the interaction with the RBD affects the
canonical LacNAc binding site of galectin-3.[23] In fact, the
1H,15N-TROSY spectrum of the galectin-3/RBD sample
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(Figure 5) exhibited the complete disappearance of specific
cross peaks, such as that for H158, conserved among galectins
and participating in hydrogen bonding with 4OH-Gal, or
R186, involved in hydrogen bonding with the GlcNAc moiety
in the complexes with LacNAc. W181, conserved and key for
the CH-p stacking interaction with Gal, was also disturbed.
Additionally, the whole S5 or S6 b-strand (V172-L177) along
the loop 177–180 were highly affected. In particular, the T175-
N179 region is hardly modified by LacNAc, but greatly
perturbed when LacNAc is a2-3 sialylated (Figure S3). Thus,
these data confirm that galectin-3 binds the RBD through the
canonical Gal binding site by specifically recognising terminal
LN, LDN and 3’SLN epitopes on the RBD.[23]
We next studied the interaction of the RBD with the N-
terminal domain of galectin-8 (galectin-8N), a tandem repeat
lectin whose N-terminal domain has partially overlapping
glycan binding preferences with galectin-3,[52, 53] although with
diverse affinities for the same epitopes.[54, 55] Strikingly, when
the RBD and galectin-8N were mixed in a 1:1 ratio, the same
conditions for galectin-3, the sample became cloudy and
unmanageable for NMR experiments. Thus, a 1:0.2 ratio (13C-
RBD:galectin) was used, resulting in a clear sample that
allowed recording the 1H,13C-HSQC (Figure 4). The observed
cross peak signal reduction was now more selective than for
galectin-3, and showed that galectin-8N binds mainly to the
3’SLN RBD glycan epitope. The interaction from the lectin
perspective (Figure S4) showed that the most affected
residues on galectin-8N were around the canonical glycan
binding site. These results permit not only underline the
different glycan binding preferences between both galectins
towards the RBD in terms of epitopes, but also the different
recognition phenomena that take place when the binding
epitopes are differently exposed or hidden, especially in
multivalent presentations, as also highlighted by others.[52]
Finally, the prototype galectin-7 was tested. Galectin-7
contains two identical glycan binding sites, forms non-
covalent homodimers, and displays the lowest glycan affinities
Figure 3. NMR identification of glycan epitopes on the RBD recognized
by galectin-3. Different regions of the 1H,13C-HSQC spectrum of RBD
alone (in black) and in the presence of 1 equivalent of galectin-3 (in
green). A) Anomeric region: signals for terminal epitopes mostly
affected by the presence of galectin-3 are annotated. B and C) Regions
of the H3-C3 and H5-C5 (respectively) correlations of terminal Neu5Ac
residues: signals for a2-3 linked residues completely disappear, while
those for the a2-6 linked are barely affected. D) Region showing the
signal of H3-C3 Gal in 3’SLN epitope. The graphical bar representation
for the % of volume reduction of selected cross peaks on 1H,13C-HSQC
of RBD upon addition of galectin-3 is given in Figure 4 upper panel.
Figure 4. Graphical bar representation for the % of cross peak volume
reduction on 1H,13C-HSQC of RBD upon adding the different lectins.
From top to bottom: galectin-3 (1 equiv), galectin-7 (1 equiv), galectin-
8N (0.2 equiv), DC-SIGN (1 equiv), MGL (1 equiv), Siglec-10
(0.2 equiv), Siglec-8 (1 equiv). Each cross peak is identified with
a number corresponding to the position on the pyranose, the residue,
and the epitope. An arbitrary threshold (transparent square) is used to
highlight the most affected signals. SNFG representation of the major
deduced epitopes on the RBD are on the right.
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reported among galectins.[52, 56] The NMR analysis of the RBD
glycans upon addition of 1 equivalent of galectin-7 revealed
that the most perturbed signals correspond to the LDN
epitope, with those for LN and 3’SLN also affected to a lesser
extent (Figure 4). These results agree with reported data that
showed that acetylation of terminal Gal moieties increased
the affinity for galectin-7,[21] although contrast respect to
3’SLN which was reported to bind weaker than LN.[21,57] From
the lectin perspective, the cross peak intensity loss upon RBD
addition affected not only amino acids at the lactose binding
pocket (W70, H50, V60, V61, N63, N52, E74), but also far
from this site (T57, S58, Q67, loops), at the F face (G76, R113,
Y106), and even at the dimer interface (V89, L90), reflecting
that most of the protein is actually affected by the interaction
(Figure S5). This evidence agrees with previous studies that
claimed an inter-domain communication upon lactose bind-
ing.[58]
The Interaction with Siglecs
The combination of the RBD with Siglec-8 produced no
changes neither on the 1H,13C-HSQC of the 13C-glycans at the
RBD (Figure 6 and Figure S6), nor in the 1H,15N-TROSY of
15N-Siglec-8 (Figure S6). Thus, Siglec-8 does not recognize
any glycan on the RBD, in agreement with the tight glycan
binding selectivity of this lectin that binds terminal 3’SLN and
SLeX, only when they are sulfated at Gal 6.[22, 59] This chemical
modification is not present in our glycosylated RBD since it
would be readily identified due to the characteristic chemical
shifts of a sulfated C6-Gal. A completely different situation
was found for Siglec-10, for which the addition of 0.2 equiv-
alents of lectin to the RBD caused a general reduction of the
cross-peak intensities of the 13C-labelled glycans. The effect
was more pronounced for the signals of terminal 3’SLN and
6’SLN epitopes (Figure 6), in agreement with the reported
selectivity for this lectin.[60] Although a preference for 6’SLN
over 3’SLN has been described, this is not appreciable from
the NMR data. Information from the lectin perspective was
not possible in this case due to the lack of access to a suitable
15N-labelled lectin for NMR.
The Interaction with C-Type Lectins DC-SIGN and MGL
The presence of 1 equivalent of DC-SIGN caused a selec-
tive intensity decrease on specific glycan 1H,13C-HSQC cross
peaks of the RBD (Figure 7). In terms of terminal epitopes,
the LeX and LDNF signals were the most affected (Figures 4
and 7).
This fact is in agreement with the reported preference of
DC-SIGN for these moieties, in which key interactions are
provided by the Fuc residue that binds at the calcium binding
site of the lectin.[20,61] The comparison with the effects
produced by 1 equivalent of MGL were markedly different
Figure 5. Galectin-3/RBD interaction deduced by NMR from the lectin
perspective. A) Superimposition of the 1H,15N-TROSY for free galectin-
3 (black) and galectin-3/RBD (green). Some affected cross peaks are
annotated: amino acids involved in LacNAc interactions are bolded;
those interacting with a2-3 sialic acid are underlined. The key signal of
W181 is squared. B) % cross peak volume reduction on the 1H,15N-
TROSY upon addition of galectin-3. S1–S6 b-strands are depicted with
grey boxes. Red and wheat horizontal lines are baselines for cross
peaks suffering 80–100% reduction and 60–80% reduction, respective-
ly. C) Cartoon and surface representation of galectin-3 bound to
LacNAc (PDB 1A3K) according to the X-Ray structure. Amino acids are
coloured based on their perturbation (% volume reduction) due to
RBD binding (threshold in B).
Figure 6. The interaction of RBD with Siglecs -8 and -10 from the
glycan perspective. Different regions of the 1H,13C-HSQC of RBD alone
(in black) and with 1 equiv. of Siglec-8 (left, superimposed in green),
and with 0.2 equivalents of Siglec-10 (right, superimposed in green).
Top and middle: regions for the C3-H3 and C5-H5 correlations of
Neu5Ac. In the presence of Siglec-8, no signal is affected, indicating
that there is no interaction, while in the presence of Siglec-10, the
signals of Neu5Ac, both a2-3 and a2-6 linked are affected, indicating
that Siglec-10 interacts with the RBD through these epitopes. The
graphical bar representation for % of volume reduction of cross peaks
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(Figures 4 and 7), permitting to identify the diverse binding
preferences of both lectins. Indeed, the presence of MGL
produced an exquisite selective reduction of the signals
corresponding to GalNAc-containing epitopes, with the
exception of 4SulLDN (Figures 4 and 7). Thus, terminal
LDN, its a2-6 sialylated version (6’SLDN), and the fucosy-
lated LDN (LDNF) are the glycans specifically recognized by
MGL.
With respect to the lectin binding site, the cross peaks on
the 1H,15N-TROSY of DC-SIGN (Figure S7) exhibited differ-
ential intensity loss upon addition of RBD. The most affected
residues belong to the calcium binding site, directly involved
in interactions with the bound Fuc (N365, D366, N367, K368).
Additionally, the signals for F313 and F374 were completely
absent in the presence of the RBD, confirming the placement
of Gal/GalNAc close to F313.[20,61, 62] Interestingly, a number
of residues at a secondary calcium site (D320, L321, Q323,
G325, T326 and W327) were also affected. The results for
MGL were completely different, reflecting the different
dynamic properties of both lectins. The presence of 0.5 equiv-
alents of RBD produced the homogeneous intensity reduc-
tion for most of the lectin with the exception of the C-terminal
fragment, while 1 equivalent produced the complete disap-
pearance of all the NMR signals in the 1H,15N-HSQC
(Figure S8). In order to confirm that the MGL glycan binding
site was indeed involved, competition experiments with
a simple GalNAc sugar were performed (Figure S9). Suitably,
the addition of 1 equivalent of GalNAc produced the
recovery of the NMR signals of the lectin, confirming that
the RBD and GalNAc compete for the same binding site.
Once the interacting glycan epitopes were experimentally
assessed, putative 3D structures were generated for the
complexes formed between the glycosylated RBD and several
lectins (galectin-3, galectin-7, galectin-8N and DC-SIGN)
using the coordinates of the X-ray crystal structures of the
lectins (PDB 4R9A, 4GAL, 5GZF, 1SL5, respectively) and
that of the RBD within the full S glycoprotein structure (PDB
6VSB) as described in the supporting information. For MGL,
an homology model was built since no crystallographic
structures are available. Given the existence of two glyco-
sylation sites at the RBD, two 1:1 complexes were generated
for each RBD/lectin system, one for the glycan at N331 and
a second for that at N343. Molecular dynamics simulations
(1 ms) were run for each complex to produce fully equilibrated
structures in water solution. The simulations revealed a multi-
tude of highly dynamical glycan-receptor contacts in addition
to those established at the canonical sugar binding sites, in
agreement with the NMR observations. The formation of
fleeting unspecific interactions between RBD glycans and the
receptor can be appreciated, often creating an interface
between the two proteins. As an example, a 3D perspective of
the possible interaction of the glycosylated RBD to galectin-3
is shown in Figure 8, while those for the other lectins are
gathered in the SI. Interestingly, interaction with galectin-3
takes place on the opposite side of RBD with respect to the
ACE2 recognition region. As a general trend, complexes
involving glycans at N343 are more compact and display
larger intermolecular contacts than those involving the
solvent-exposed glycans at N331 (see SI).
Overall, our study has allowed identifying N-linked glycan
epitopes located in the RBD of the spike protein from SAR-
Figure 7. Different interactions of the RBD with C-type lectins DC-SIGN and MGL from the glycan perspective. Selected regions of the 1H,13C-
HSQC of RBD alone (in black), with 1 equiv. of DC-SIGN (left, superimposed in green), and with 0.2 equivalents of MGL (right, superimposed in
green). A) Anomeric region and graphical bar representation for the % of volume reduction (also in Figure 4 with additional cross peaks)
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CoV-2 that serve for the recognition of host lectins, which may
contribute to viral infection and subsequent immune exacer-
bation. An additional analysis of binding and competition
using the fully glycosylated spike trimer, will help us test the
possible interfering ability of these human lectins either by
ACE2 binding competition or by hampering the fusion of the
virus with human cells.
Conclusion
The RBD fragment of the SARS-CoV-2 S glycoprotein
with 13C glycan labelling has been generated. The great
sensitivity provided by 13C opens the door to significant
opportunities for exhaustive NMR analysis of its glycoprofile
and its molecular recognition features. Thus, by employing an
NMR-based methodology, which avoids sample digestions
and derivatizations, most of the 1H and 13C NMR glycan
resonances of the intact (folded) glycoprotein in solution have
been assigned, allowing to characterize the specific terminal
glycan epitopes exposed on the antennae of the RBD N-
glycans. Although the current analysis do not allow for fully
quantitative occupancy determination and site specific iden-
tification at N331 and N343, it has provided unprecedented
structural details. Thus, besides the expected LN, 3’SLN, and
6’SLN terminal moieties, the presence of LDN and its
fucosylated LDNF derivative have been assessed. Whereas
the former has been detected in a trimer-stabilized version of
the SARS-CoV-2 S protein, the presence of the LDNF
epitope was unexpected. Indeed,[15] LDN motifs have been
found on several mammalian glycoproteins and observed in
HEK293-produced glycoproteins.[63] In contrast, the LDNF
epitope has been mainly related to pathogens. Additionally, 4-
O-sulfated and a2-6 sialylated LDN derivatives, not previ-
ously reported either, have also been identified as terminal
epitopes, together with the LeX epitope. Overall, our analysis
highlights the presence of important levels of N-acetyl-
galactosylation and hyper-fucosylation at the terminal chains
of the RBD N-glycans, revealing glyco-epitopes not observed
in previous MS-based analysis.[13–16] Interestingly, the compar-
ison with a different glycoprotein produced exactly under the
same conditions suggests a relationship between the observed
high levels of GalNAc and Fuc contents with the protein
structure. The exhaustive NMR analysis has also allowed
disclosing the main N-glycan scaffold, being complex bian-
tennary, core fucosylated, while lacking bisecting GlcNAc and
elongated antennas involving type I polyLacNAc sequences.
The interaction of the glycosylated RBD with a panel of
human lectins has also been scrutinized. The 13C-glycan
labeling of the RBD has permitted to exploit the 1H,13C-
HSQC spectrum of the RBD to report on the specific glycan
epitopes recognized by each lectin, affording the correspond-
ing glycan binding selectivity. Thus, while galectins-3 and -7
recognize the LN, LDN and 3’SLN motifs on the RBD,
galectin-8N seems to prefer exclusively the 3’SLN epitope.
Siglecs-8 and -10 demonstrated markedly differences, with
Siglec-8 unable to recognize any of the glycan epitopes on the
RBD, while Siglec-10 interacting with both 3’SLN and 6’SLN.
For the C-type lectins, DC-SIGN exhibited selectivity for the
two fucosylated terminal epitopes LeX and LDNF, while
MGL showed exquisite selectivity for all GalNAc containing
epitopes, except for the 4-O-sulfated derivative. The comple-
mentary information obtained from the 15N-lectin based
experiments permitted to assess that binding occurs through
the canonical glycan binding site for each of the lectins
(except for Siglec-10). Importantly, all the binding studies
have been carried out by using the intact (folded) form of the
RBD glycoprotein in solution, allowing to propose atomistic
3D models for the corresponding complexes.
This study paves the way to unveiling the interlaces roles
of glycosylation patterns and cell receptors in SARS-CoV-2
infection mechanisms in the cell, particularly the recognition
of tissue-dependent ACE2 by full-length glycosylated spike
protein (S). Such studies are currently ongoing in our labs.
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